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Demyelination and axonal injury are the key pathological processes in multiple sclerosis
(MS), driven by inflammation and oxidative stress. Acrolein, a byproduct and instigator of
oxidative stress, has been demonstrated as a neurotoxin in experimental autoimmune
encephalomyelitis (EAE), an animal model of MS. However, due to the invasive
nature of acrolein detection using immunoblotting techniques, the investigation of
acrolein in MS has been limited to animal models. Recently, detection of a specific
acrolein-glutathione metabolite, 3-HPMA, has been demonstrated in urine, enabling
the noninvasive quantification of acrolein for the first time in humans with neurological
disorders. In this study, we have demonstrated similar elevated levels of acrolein in
both urine (3-HPMA) and in spinal cord tissue (acrolein-lysine adduct) in mice with EAE,
which can be reduced through systemic application of acrolein scavenger hydralazine.
Furthermore, using this approach we have demonstrated an increase of 3-HPMA in both
the urine and serum of MS patients relative to controls. It is expected that this noninvasive
acrolein detection could facilitate the investigation of the role of acrolein in the pathology
of MS in human. It may also be used to monitor putative therapies aimed at suppressing
acrolein levels, reducing severity of symptoms, and slowing progression as previously
demonstrated in animal studies.
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INTRODUCTION
Multiple sclerosis (MS) is a presumed autoimmune demyelinating central nervous system disease
that affects approximately 2.5 million people worldwide (1). To date, the etiology of MS remains
incompletely characterized and, as a result, therapeutic approaches are limited and highly reliant
upon suppressing or modulating the overactive immune system to alleviate symptoms and
decelerate disease progression (1, 2). A growing number of studies have implicated reactive
oxygen species as key mediators of pathological processes associated with the disease, including
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demyelination and axonal injury (3, 4). However, application
of free radical scavengers to curtail oxidative stress conferred
limited and somewhat variable symptomatic improvement in
the experimental autoimmune encephalomyelitis (EAE) model,
prompting investigation of alternative compounds associated
with oxidative stress for pharmacological targeting (1–3).
Acrolein, 2-propenal, produced by way of reactive oxygen
species instigated lipid peroxidation, has emerged as a potent
pro-inflammatory neurotoxin, capable of reacting with lipid,
protein, and DNA and perpetuating inflammation and oxidative
stress through a feed-forward mechanism (5–11). Recently,
acrolein has been shown to be elevated significantly in EAE,
an animal model of MS (12), and to inflict damage to myelin,
axolemma, and mitochondria both directly and indirectly (13–
18). Furthermore, attenuation of acrolein through treatment
of EAE with hydralazine, an FDA-approved anti-hypertensive
that is known to be an acrolein scavenger (16, 17, 19–23),
resulted in a reduction of central nervous system (CNS) acrolein
levels which correlated with improved behavioral outcomes and
delayed symptomatic onset in EAE mice (12). These data suggest
a pathogenic role of acrolein in EAE. It is thus important to
determine whether acrolein has a similar role in the pathogenesis
of MS. However, clinical determination of acrolein levels in
vivo in MS patients has not been conducted due to technical
difficulties.
Due to recent advances in acrolein detection techniques,
minimally invasive quantification of systemic acrolein levels
can be achieved through the measurement of 3-hydroxypropyl
mercapturic acid (3-HPMA), a specific acrolein-glutathione
metabolite, in urine using LC/MS/MS (24–27). Recently, the
3-HPMA quantification method has been successfully applied
in an animal model of spinal cord injury (27). In contrast to
previous methods utilized exclusively in animal studies, such as
immunoblotting which required animal euthanasia to harvest
fresh CNS tissue (12, 16, 28–32), this approach allows for the
assessment of acrolein levels without the need of sacrificing the
animal (27, 33), and thus permits the translation of the 3-HPMA
measurement technique to clinical scenarios.
In the current study, using this non-invasive technique, we
have found that 3-HPMA levels are significantly elevated in
both urine and serum in MS patients compared to healthy
individuals. This indicates that 3-HPMA measurement is a
feasible, effective assessment of systemic acrolein level in MS
patients. The evidence of elevated acrolein in MS in both human
patients and animal models is consistent with the proposed
notion that acrolein is involved in the pathogenesis of MS.
Considering the demonstrated toxicities of acrolein in myelin
and axons, we speculate that acrolein is likely a therapeutic
target in MS. Furthermore, this method has also made it possible
for acrolein to serve as a biomolecule that could potentially
be noninvasively monitored to aid in diagnosis, predict disease
course, and guide treatment regimens.
Abbreviations: 3-HPMA, 3-hydroxypropyl mercapturic acid; CNS, Central
nervous system; EAE, Experimental autoimmune encephalomyelitis; MS, Multiple
sclerosis; PPMS, Primary progressive multiple sclerosis; RRMS, Relapsing-
remitting multiple sclerosis; SPMS, Secondary progressive multiple sclerosis.
MATERIALS AND METHODS
Animal Preparation
Rodent studies were conducted in accordance with guidelines
mandated by the Purdue Animal Care and Use Committee
at Purdue University, West Lafayette, IN, USA. The current
study was specifically approved by the Purdue Animal Care
and Use Committee. Eight-week-old C57BL/6 female mice
(Harlan Laboratories, Indianapolis, IN, USA) were maintained
in laboratory animal housing facilities for 2 weeks prior to EAE
induction to minimize potential effects of stress.
EAE Model Induction and Behavioral Assessment
Ten-week-old mice were injected subcutaneously over rostral
and caudal ends of the spinal column with 0.1mL MOG35-
55/CFA emulsion (EK-0115, Hooke Laboratories, Lawrence, MA,
USA). A 0.1mL volume of deconjugated pertussis toxin (EK-
0115, Hooke Laboratories) was administered intraperitoneally
on the day of MOG application and again 22–26 h later to aid
in permeabilizing the blood brain barrier. A widely utilized 5-
point behavioral scoring system (12, 34) was employed to assess
motor function by monitoring signs of paralysis and observing
gait when animals were placed on ametal grate. Mice were scored
in accordance with the following scale: 0, no deficit; 1, limp tail
only; 2, hind limb paresis, without leg dragging; 3, partial hind
limb weakness with one or both legs dragging; 4, complete hind
limb paralysis; 5, moribund, paralysis in hind limbs and possibly
in one forelimb. The behavioral score and weight of animals were
determined and recorded daily for the duration of the study.
Irreversible dehydration or 20% loss of body weight were
used as criteria for humane endpoints requiring euthanasia
prior to experimental endpoints. No animals died prior to
the experimental endpoint in this study. Ketoprofen (5 mg/kg,
subcutaneous) was used to alleviate distress or suffering indicated
by quiet posture, decreased activity, self-mutilation, or abnormal
respiratory patterns.
Dot Immunoblotting
Spinal cords were harvested from mice following exsanguination
and perfusion of oxygenated Kreb’s solution as described in
prior publications (12). The procedure of exsanguination was
performed under anesthesia with a ketamine (90mg/kg)-xylazine
(10 mg/kg) mixture through intraperitoneal injection. The
anesthetized mice were then perfused transcardially with a cold
(15◦C) oxygenated Krebs solution to remove the blood and
lower core temperature. The fresh tissues were incubated with
1% Triton solution and Protease Inhibitor Cocktails, (Sigma-
Aldrich, Product #: P8340) homogenized (Kontes Glass Co.) and
incubated on ice for at least 1 h. Samples were then centrifuged at
13,500 g and 4◦C for a minimum of 30min.
BCA protein assay was performed to ensure equal loading
for all samples. Samples were transferred to a nitrocellulose
membrane using a Bio-Dot SF Microfiltration Apparatus (Bio-
Rad, Hercules, CA, USA). The membrane was blocked for 1 h
in blocking buffer (0.2% Casein and 0.1% Tween 20 in PBS)
and transferred to a solution where polyclonal rabbit anti-
acrolein antibody (Novus Biologicals) was dissolved, with a
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ratio of 1:1,000, in blocking buffer with 2% goat serum and
0.025% sodium azide, for 18 h at 4◦C. The membrane was then
washed blocking buffer and incubated for 1 h in a solution of
1:10,000 alkaline phosphatase conjugated goat anti-rabbit IgG
(VECTASTAIN ABC-AmP Kit). Final washes of the blocking
buffer followed by 0.1% Tween 20 in Tris-buffered saline were
performed before the membrane was exposed to substrate of
the ABC-AMP kit and visualized by chemiluminescence. Band
density was quantified using Image J (NIH) and expressed as
arbitrary unit.
Animal Urine Collection
Mice were housed in metabolic cages, designed to obtain urine
samples, for 12–24 h. Regular food and water were supplied
during the sample collection period. Samples of approximately
500µL were obtained from each animal at peak behavioral deficit
between days 21 and 23. Samples were then transferred to 1mL
centrifuge tubes and frozen at −80◦C until biochemical analyses
were performed.
Hydralazine Application
Hydralazine hydrochloride (Sigma, St. Louis, MO, USA) was
dissolved in phosphate buffered saline, sterilized through a filter,
and subsequently stored at 4◦C. Hydralazine at a dosage of 1
mg/kg (Body Weight) was applied daily through intraperitoneal
injections (IP), commencing from the day of induction until the
end of study period (22 days post induction).
Human Subject Enrollment
All human specimens were collected at the Indiana University
Multiple Sclerosis Center, Department of Neurology, Indiana
University School of Medicine, Indianapolis, IN, USA. Criteria
for subject selection consisted of an MS diagnosis and that the
patient not be receiving corticosteroids at the time of the sample
collection. In this regard, it is important to note that many
patients were on various FDA-approved MS immunotherapies
at the time of sample collection. This study was carried out in
accordance with guidelines set forth in the protocol approved
by the Indiana University Human Subjects Institutional Review
Board. All patients provided written informed consent in
accordance with the Declaration of Helsinki using a consent form
approved by the Institutional Review Board.
Clinical Urine Collection
Subjects were provided with a specimen cup, without
preservative, for urine sample collection. Urine samples
were then pipetted into labeled cyrovials and immediately stored
at−80◦C prior to being transported to Purdue University on dry
ice. Upon arrival, samples were immediately stored at −80◦C
until analysis.
Clinical Serum Collection
Venous blood samples were obtained by standard technique
(BD Vacutainer R© Safety-LokTM Blood Collection Set 23, Gauge
3/4 Inch Safety Needle, 12 Inch Tubing Sterile) and directly
placed into a BD Vacutainer R© Plus Venous Blood Collection
Tube Serum Tube Clot Activator 13 × 100mm 6mL BD
HemogardTM Closure Plastic Tube. Following collection, samples
were incubated for 15min at room temperature to facilitate
clotting. The samples were then centrifuged at 2,800 rpm for
15min (Beckman GS-6R) and transferred to a labeled cyrovial
and stored at Thermo Scientific −80◦C. Samples were then
transported to Purdue University on dry ice and stored at−80◦C
until analysis.
3-HPMA Quantification Using LC/MS/MS
and Standard Preparation
3-HPMA Quantification
3-hydroxypropyl mercapturic acid (3-HPMA) was quantified in
urine according to Eckert et al. (35). Solid phase extraction with
Isolute ENV+ cartridges (Biotage, Charlotte, NC) was used to
prepare each sample before LC/MS/MS analysis. Cartridges were
conditioned with 1mL of methanol, 1mL of water, and 1mL of
0.1% formic acid in water in succession. Urine or serum sample
aliquots of 500 µL were combined with 200 ng of deuterated 3-
HPMA (d3-3-HPMA) (Toronto Research Chemicals Inc., New
York, Ontario), 500 µL of 50mM ammonium formate and 10
µL of undiluted formic acid and pipetted into the prepared
ENV+ cartridges. The cartridges were then washed twice with
1mL of 0.1% formic acid and 1mL of 10% methanol/90% 0.1%
formic acid in water in succession. The cartridges were dried with
nitrogen gas and subsequently eluted with three volumes of 600
µL methanol + 2% formic acid which were combined and dried
in a rotary evaporation device. Samples were reconstituted in 100
µL of 0.1% formic acid prior to LC/MS/MS analysis.
Quantification of 3-HPMA in the samples was determined
using an Agilent 1200 Rapid Resolution liquid chromatography
(LC) system coupled to an Agilent 6460 series QQQ mass
spectrometer (MS) and a Waters Atlantis T3 2.1mm x 150mm,
3µm column for LC separation. Water + 0.1% formic acid and
acetonitrile + 0.1% formic acid were used as buffers. The peak
retention time of 3-HPMA/d3-3-HPMA was 6.8min. Multiple
reaction monitoring was used for MS analysis. A more detailed
procedure is outlined in previous publication (27).
Creatinine Assay
Creatinine quantification was performed to provide an internal
standard normalize urine 3-HPMA measurements. Sample
creatinine concentrations were determined through the use of a
urinary creatinine assay kit (Cayman Chemical Company, Item
No. 500701). Urine samples were diluted for 12× and 24×
prior to measurement and alkaline picrate solution was prepared
following the procedure delineated in the assay manual. The
diluted samples and creatinine standards were then loaded into
a 96 well plate and incubated with the alkaline picrate solution
at room temperature for 20min. Absorbance at 490–500 nm
was determined using a standard spectrophotometer and the
results were recorded as the initial reading. Following the initial
reading, 5 ul of acid solution was added to each sample and
incubated on a shaker at room temperature for an additional
20min. A spectrophotometer (absorbance at 490–500 nm) was
used again to determine the final reading following addition of
the acid. The differences between the initial and final absorbance
measurements were used for quantitative analysis.
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BSA assessment was used as a normalization factor for the
serum 3-HPMA measurements. Protein concentrations using
bovine serum albumin were quantified using the Bicinchoninic
Acid protein assay kit (Pierce, Rockford, IL, USA). Serum
samples were prepared in a 1:100 dilution and loaded into a 96
well plate along with BSA standards in triplicates. BSA reagent
was then added to all wells and the samples were incubated
at 37C for 30min. Following incubation the absorbance of the
samples at 560–570 nm was determined using SPECTRAMAX
(Molecular Devices, Sunnyvale, CA, USA).
Statistical Analysis
Student’s t-test (unpaired, two-tailed) was used to compare
various acrolein measurements between control and EAE/MS
groups in different conditions. For comparisons involving
three or more groups, ANOVA and post-hoc Newman–Keul’s
test were used to compare the data. Linear correlation was
expressed by Pearson correlation coefficient (r). Results are
expressed as mean ± SEM. P < 0.05 was considered statistically
significant.
RESULTS
CNS and Systemic Elevation of Acrolein in
EAE Mice
Systemic acrolein levels based on urine samples in EAE mouse
were determined through the quantification of 3-HPMA using
LC/MS/MS (27). Urine was collected from controls and EAE
mice during pre-symptomatic period of days 7–9, and when
peak deficit occurred at days 21–23 post induction (Figure 1).
At days 7–9, EAE mice displayed an elevated level of 3-HPMA
(27.3 ± 4.2 µg/mg creatinine) which is significantly higher than
control mice (16.9 ± 0.8 µg/mg creatinine, p < 0.05). Similarly,
EAE mice demonstrated significantly elevated urine 3-HPMA
levels (30.5 ± 3.6 µg/mg creatinine) relative to their healthy
counterparts (19.5 ± 1.0 µg/mg creatinine, p < 0.05) (Figure 2)
at days 21–23 post induction. In addition to urine acrolein levels,
we also quantified the correspondent acrolein level in spinal
cord tissue using dot immunoblotting. Specifically, both EAE and
control groups were sacrificed at day 28 post induction and spinal
cord tissue was harvested to assess local acrolein concentrations
within the CNS using a dot immunoblotting assay. We have
found that EAE mice exhibited significantly elevated intrinsic
levels of acrolein-lysine adducts (19.1 ± 1.8 au) relative to the
control group (12.5 ± 0.7 au, p < 0.01) (Figure 3). A correlation
analysis between urine 3-HPMA and spinal cord tissue acrolein-
lysine adducts in EAE mice at the peak symptomatic stage
has revealed a significant positive relationship with a Pearson
correlation coefficient (r) value of 0.87 (p < 0.005) (Figure 4).
In a separate group, EAE mice received daily IP injection of
hydralazine treatment (1 mg/kg), starting the day of induction,
and the urine was collected at 21–23 post induction, and the
spinal cord tissue were collected 28 days post induction and
treatment. As indicated in Figure 5, the value of urine 3-HPMA
in EAE plus hydralazine group (9.25 ± 1.54 µg/mg creatinine)
is significantly less than that in EAE group when examined 21–
23 days post induction (29.9 ± 3.6 µg/mg creatinine, P < 0.01).
FIGURE 1 | Behavioral deficits in EAE mice following induction. A total of 9
mice were subjected to MOG injection. The same number of age matched
uninured mice were used to serve as controls. The motor deficits typical of
EAE were scored daily for 4 weeks. The motor function of control mice was
also observed for the same period of time for comparisons. The mean value
(and SEM) of both control and EAE mice are plotted against time post
induction. The two shaded areas indicate the time periods (7–9 days) and
(21–23 days) when urine 3-HPMA samples were collected and assessed using
LS/MS/MS. Acrolein-lysine adduct levels in spinal cord tissue were quantified
using dot blot. Both urine 3-HPMA and tissue acrolein-lysine adduct were
used to assess acrolein levels. Note the steady rises of EAE score beginning at
around 11–12 days and peak attained around 21–22 days post induction.
Data expressed as mean ± SEM.
Similar, the value of acrolein-lysine adducts in spinal cord tissue
(14.2 ± 1.1 au) is also significantly less than that in EAE group
(19.1± 1.8 au, P < 0.05).
Multiple Sclerosis Patients Exhibited
Increased 3-HPMA in Urine and Serum
Urine and serum samples were collected from diagnosed MS
patients (n = 40) and volunteer healthy controls consisting of
mainly office staff and family members of patients (n = 23).
Among MS patients, there were 27 females and 13 males,
while in the control group, there were 18 females and 5
males. The average age at the time of specimen collection
was 45.9 years for MS patients and 47.7 years for control
individuals. Among MS patients, there were 31 who were
diagnosed as relapsing-remitting MS (RRMS), 8 were diagnosed
as secondary progressive MS (SPMS), and 1 as primary
progressive MS (PPMS). There were 38 patients who were
diagnosed as not in the relapsing stage and 2 (one as SPMS
and another as RRMS) were in relapse at the time of specimen
collection. Only non-smokers in both MS and control groups
were included in this study. Acrolein content within the
specimens (both urine and serum) was estimated through the
assessment of 3-HPMA using LC/MS/MS. Figure 6A depicts
3-HPMA measurements using scatter plot. Mean 3-HPMA
levels detected in the urine of MS patients (1.094 ± 0.212
µg/mg creatinine) were significantly elevated relative to healthy
controls (0.570 ± 0.082 µg/mg creatinine, p < 0.05). Results
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FIGURE 2 | Determination of acrolein concentration through urine 3-HPMA
measurement in control and EAE mice during pre or peak symptomatic stage.
(A) Chemical reaction of acrolein with glutathione (GSH) and production of
subsequent metabolites OPMA and 3-HPMA. (B) Bar graph depicts the ratio
of 3-HPMA and creatinine measured in urine of control and EAE mouse. Urine
samples were collected approximately 7–9 days and 21–23 days after MOG
injection in EAE mouse which correspond to pre and peak symptomatic stage
(see also Figure 1). Urine samples were also collected from age matched
control mice at similar time periods. Each urine sample represents an
accumulative volume of a 24 h period. Note the increase of 3-HPMA in urine in
EAE mice in both pre and peak symptomatic periods when compared to
control group (*P < 0.05 when compared to control, ANOVA and post-hoc
Newman-Keul’s test). N = 9 in each group of 3-HPMA measurement in urine.
Data expressed as mean ± SEM.
obtained following quantification of 3-HPMA in patient serum
specimens corresponded with the data obtained from urine
analysis for both the MS group (0.065 ± 0.009µg/g protein)
and the control group (0.036 ± 0.004µg/g protein), in which
MS patients demonstrated a significant elevation compared to
control (p< 0.05, Figure 6B). Interestingly, a correlation analysis
between 3-HPMA measurements in MS patient urine and
serum samples, revealed a significant positive relationship with
a Pearson correlation coefficient (r) value of 0.75 (p < 0.0001)
(Figure 7).
DISCUSSION
In the current study, using a non-invasive method, we have
shown that 3-HPMA, a stable acrolein metabolite, is significantly
elevated in urine in EAE mice at pre-symptomatic stage (7–9
days post induction) and peak symptomatic stage (21–23 days
post induction). Such elevation of 3-HPMA in urine is correlated
with an increase of acrolein in spinal cord tissue, and both
FIGURE 3 | Determination of acrolein changes in spinal cord tissue by
immunoblotting in EAE mice. The acrolein-lysine adducts in control and in EAE
were detected using Bio-Dot SF microfiltration apparatus. Band intensities
were analyzed using image J (NIH) and expressed in arbitrary units. Note the
scatter plot demonstrated an increase of acrolein-lysine adducts in EAE.
(*P < 0.01 when compared to control, t-test). N = 9 in each group of acrolein
measurement in tissue.
FIGURE 4 | Correlation of 3-HPMA levels in urine and acrolein-lysine adducts
in spinal cord tissue of EAE mice. The urine 3-HPMA is plotted against tissue
acrolein-lysine adducts for 9 EAE mice showing the relationship between these
two parameters. As indicated, the increase of urine 3-HPMA correlated with
the elevation of tissue acrolein-lysine adducts. Statistical analysis of correlation
revealed a Pearson correlation coefficient (r) value of 0.87 (p < 0.005, two
tailed).
can be reduced with the application of hydralazine (1 mg/kg).
Furthermore, we have also revealed that 3-HPMA is significantly
elevated in the urine and serum of MS patients compared to
healthy controls. To our knowledge, this is the first reported
study to non-invasively quantify acrolein, an alleged pathogen in
myelin and neuronal damage in MS, in both human and animal
models using a 3-HPMA assay. Notably, we also present the
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FIGURE 5 | Hydralazine effectively suppressed acrolein-lysine adducts in
spinal cord and 3-HPMA in urine in EAE mice. In EAE plus hydralazine
treatment group, hydralazine (1 mg/kg) was administered IP daily starting
immediately following induction. Urine samples in both groups were collected
21–23 days post induction when the behavior deficits peak. Dotted line
represent the value from age matched mice served as controls. Note the
suppression of either acrolein-lysine adducts in spinal cord tissue, or 3-HPMA
in urine, in EAE plus hydralazine group compared to EAE group (*P < 0.05;
**P < 0.01, ANOVA and post-hoc Newman-Keul’s test). N = 9 in each group
of acrolein measurement in tissue and 3-HPMA measurement in urine.
first clinical evidence that MS patients exhibit elevated systemic
acrolein concentrations.
Based on the established evidence of neurotoxicity of acrolein
(5, 6, 13–18) and its elevation in both EAE mice and human MS
patients (12), we suggest that acrolein likely plays a critical role in
neuronal tissue damage characteristic ofMS. Considering the fact
that anti-acrolein treatment has been shown to reduce acrolein
levels in the current and prior studies, and offer neuroprotection
in EAE mice (12), we speculate that acrolein may also serve
as a therapeutic target for pharmacological intervention and
treatment evaluation for anti-acrolein therapy in a clinical
setting. An acrolein-based therapeutic approach may represent
a novel strategy in the management of MS, a devastating
neurological condition with limited therapeutic approaches for
symptom management.
One interesting and unexpected finding of the current
study is that urine 3-HPMA is elevated before the emergence
of symptoms in EAE mice. We feel this likely represents
the augmented level of immunological/inflammatory activity
that precedes the motor deficits in this animal model of
MS. Consistent with this, it has been shown that significant
membrane damages can be detected before the emergence of
symptoms in EAE mice (36) while acrolein is known to inflict
membrane destruction (13). Similarly, allodynia, a pathology
which can stem from inflammation and acrolein (30), can
be detected before any signs of neurological deficits in EAE
mice (37). These observations are also consistent with the in
vitro and ex vivo data that acrolein-mediated damage is time-
dependent, meaning the in vivo behavioral deficits likely appear
following a continuous acrolein exposure (15, 17). Therefore,
the elevation of urine 3-HPMA could be used as a diagnostic
and/or monitoring tool to associate and predict the emergence of
behavioral impairments such as motor deficits, neuropathic pain,
and other common MS symptoms. However, while it is possible
that pre-symptomatic neuro-inflammation can be detected in
human, cautions needs to be taken when translating such results
from animal to human, considering the cause of the disease in
human MS and in EAE are obviously different.
The success of non-invasive acrolein detection in urine would
not only allow longitudinal animal in vivo studies of acrolein
dynamics, evaluation of potential anti-acrolein therapies, but
also permits the detection of acrolein in human patients (24–
27). As such, the clinical component of this study exclusively
relied on 3-HPMA quantification as an acrolein detection
method. However, 3-HPMA was independently quantified in
both urine and serum samples to ensure the reliability of the
measurements, and both showed significant and correlative
elevation (Figure 7), It is worth noting that, while most
of reported detection of 3-HPMA have been conducted in
urine, we have observed similar phenomenon in blood in
the same group of animal subjects animal, which not only
further strengthening the validity of 3-HPMA measurements
in both urine and serum, but also facilitate the utility of such
method.
One limitation of the current human study is the low number
of total participations patients, as well as the uneven distribution
of patients in some sub groups which potentially hindered
statistical analysis. The comparison between patients subgroups,
such as male (13) vs. females (27); RRMS (31) and SPMS (8);
remission (38) vs. relapse (2), did not yield significance. A
more comprehensive longitudinal study with greater statistical
power could potentially reveal how 3-HPMA levels correlate with
active structural lesions (such as brain and spinal cord lesions
identified using neuroimaging), sex, symptomatic presentations
(remitting vs. relapsing stage), symptom emergence and
progression (RRMS, SPMS, and PPMS), and further solidify
the role of acrolein in pathological processes underlying
clinical MS.
Furthermore, acrolein detection could help patient selection
for better response, as well as to optimize the dosage regimen for
an anti-acrolein treatment. For example, while the average of 3-
HPMA among MS patients is significantly higher than control,
it is conceivable that some MS patients exhibited 3-HPMA
values that are closer to controls (Figure 6). Understandably,
patients with higher acrolein level may benefit from anti-
acrolein therapy more than those without such feature. Non-
invasive acrolein detection also allows for dosage determination
of acrolein scavengers to be tailored to a specific patient
and to assess the effectiveness of acrolein-scavenging therapy.
Taken together, the non-invasive detection of acrolein described
in the current study could potentially play a critical role in
the treatment of illness that is associated with high level of
acrolein.
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FIGURE 6 | Determination of acrolein concentration through urine and serum 3-HPMA measurement in MS patients and healthy individuals. The MS patient group
including 31 relapsing-remitting (RRMS), 8 secondary progressive (SPMS), and 1 primary progressive (PPMS) types of MS. (A) A scatter plot including all the data
points to reveal the range and distribution of measured values of urine 3-HPMA. Solid lines indicate mean 3-HPMA in both MS and healthy control individuals. Note
that while many data points of MS patients were distributed in the same range as that of control, there were still multiple points of MS which were greater than that in
control, some by multiple folds. Specifically, the mean concentration of 3-HPMA is 1.094 ± 0.212 µg/mg creatinine for MS patients (N = 40) and 0.570 ± 0.082
µg/mg creatinine for healthy individuals (N = 23). Note the increase of 3-HPMA in urine in MS patients. (*: P < 0.05, t-test). (B) A scatter plot including all the data
points to reveal the range and distribution of measured values of serum 3-HPMA. Solid lines indicate the mean 3-HPMA level in both MS patients and control
individuals. Note that while many data points of MS patients were distributed in the same range as that of controls, there were still multiple points of MS that were
greater than that of control, some by multiple folds. The mean concentration of 3-HPMA is 0.065 ± 0.009µg/g protein for MS patients (N = 40) and 0.036 ±
0.004µg/g protein for healthy individuals (N = 23). Note the increase of 3-HPMA in serum among MS patients. (*: P < 0.05, t-test).
FIGURE 7 | Correlation of 3-HPMA levels in urine and serum in MS patients.
The urine 3-HPMA is plotted against serum 3-HPMA for 39MS patients
showing the relationship between these two parameters. Urine and serum
were collected at the same time for all patients. As indicated, the increase of
urine 3-HPMA seems to be correlated with the elevation of serum 3-HPMA.
Statistical analysis of correlation revealed a Pearson correlation coefficient (r)
value of 0.75 (p < 0.0001, two tailed).
Although we have detected elevated acrolein in both locally
through spinal cord tissue and systemically through urine in our
animal studies, there are some differences worth noting which
could shed light on the future clinical studies on the differences
between MS and other neurological conditions such as spinal
cord injury. In the current study of EAE, the degree of increase of
acrolein elevation in urine is 1.56 greater than control (days 21–
23), which is significantly correlated to the increase of acrolein
in spinal cord tissue (1.53 greater than control), indicative that
acrolein is elevated proportionally in both CNS tissue and general
circulation. This differs from the context of an acute neurological
injury, such as SCI, where the elevation of acrolein in spinal cord
is 4.5 greater than control while urine 3-HPMA only increased
by a factor of 1.8 (27). This may reflect the fact that spinal
cord tissue damage in SCI initiated by mechanical trauma, is
more severe, and causes an intense acute increase of acrolein
locally at the injury site, and not diffusely like CNS damage in
MS. This may also explain the lesser degree of elevation of 3-
HPMA in urine post-SCI because the acrolein concentration is
generated from a single lesion site and significantly diluted upon
entering systemic circulation. In contrast, MS displays much
more diffusive pathology over longer time course, which may
explain the similar degree of elevation of acrolein in both CNS
and systemic measurements observed in MS animal models. This
also suggests that a systemic determination of acrolein in SCI
maybe an underestimation of acrolein in spinal cord tissue, which
could be several factors higher than that in observed in urine
(27). This is in contrast to what is observed in EAE mice, where
the systemic measurement of 3-HPMA in urine is a relatively
accurate reflection of acrolein level in spinal cord tissue. One
related phenomenon is the degree of suppression of acrolein by
hydralazine seems to be more prominent in urine than in spinal
cord (Figure 5). This is likely due to the more direct access of
systemic circulation to drugs through IP injection. Therefore, the
effectiveness of anti-acrolein effect of hydralazine based on urine
may be an overestimate of its effect in spinal cord tissue.
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In summary, the observation of the elevated 3-HPMA levels
in MS patients using non-invasive measures will not only
further strengthen the proposed pathological role of acrolein
in MS, but also present possibilities for its utility in the
diagnosis and treatment assessment of MS. Clinical applicability
of acrolein-scavenging is further augmented by the availability
of multiple off-label FDA-approved acrolein-scavengers, most
notably hydralazine, phenelzine, and dimercaprol [(8, 12, 17, 21–
23, 31, 38–42)]. Taken together, the efficacious application of
non-invasive 3-HPMA measurements in MS, along with the
availability of acrolein-suppressing drugs, has underscored the
translational nature of acrolein research potentially leading to
significant improvements for both the diagnosis and treatment
of MS clinically.
AUTHOR CONTRIBUTIONS
RS and DM conceived and designed the experiments. MT, JT, LZ,
GA, RT, LH, and NR performed the experiments. MT, LZ, GA,
JT, NR, and RS analyzed the data. MT, JT, RS, and DM wrote the
manuscript. All authors discussed the results and commented on
themanuscript, and approved the final version of themanuscript.
FUNDING
This work was supported by an Indiana CTSI CBR/CTR Pilot
Program Grant (RR025761 to RS and DM), the Indiana State
Department of Health (204200 to RS), the National Institutes of
Health (NS073636 to RS).
REFERENCES
1. Compston A, Coles A. Multiple sclerosis. Lancet (2008) 372:1502–17.
doi: 10.1016/S0140-6736(08)61620-7
2. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy
of multiple sclerosis via animal models: 70 years of merits and culprits
in experimental autoimmune encephalomyelitis research. Brain (2006)
129:1953–71. doi: 10.1093/brain/awl075
3. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive
oxygen and nitrogen species. Brain Pathol. (1999) 9:69–92.
doi: 10.1111/j.1750-3639.1999.tb00212.x
4. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the
pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J
Neurol. (2004) 251:261–8. doi: 10.1007/s00415-004-0348-9
5. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-
hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med.
(1991) 11:81–128. doi: 10.1016/0891-5849(91)90192-6
6. Kehrer JP, Biswal SS. The molecular effects of acrolein. Toxicol Sci. (2000)
57:6–15. doi: 10.1093/toxsci/57.1.6
7. Shi R, Luo L. The role of acrolein in spinal cord injury. Appl Neurol. (2006)
2:22–7.
8. Hamann K, Shi R. Acrolein scavenging: a potential novel mechanism of
attenuating oxidative stress following spinal cord injury. J Neurochem. (2009)
111:1348–56. doi: 10.1111/j.1471-4159.2009.06395.x
9. Shi R, Rickett T, Sun W. Acrolein-mediated injury in nervous
system trauma and diseases. Mol Nutr Food Res. (2011) 55:1320–31.
doi: 10.1002/mnfr.201100217
10. Park J, Muratori B, Shi R. Acrolein as a novel therapeutic target for motor
and sensory deficits in spinal cord injury.Neural Regen Res. (2014a) 9:677–83.
doi: 10.4103/1673-5374.131564
11. Shi R, Page JC, Tully M. Molecular mechanisms of acrolein-mediated myelin
destruction in CNS trauma and disease. Free Radic Res. (2015) 49:888–95.
doi: 10.3109/10715762.2015.1021696
12. Leung G, SunW, Zheng L, Brookes S, Tully M, Shi R. Anti-acrolein treatment
improves behavioral outcome and alleviates myelin damage in experimental
autoimmune enchephalomyelitis mouse. Neuroscience (2011) 173:150–55.
doi: 10.1016/j.neuroscience.2010.11.018
13. Luo J, Shi R. Acrolein induces axolemmal disruption, oxidative stress, and
mitochondrial impairment in spinal cord tissue. Neurochem Int. (2004)
44:475–86. doi: 10.1016/j.neuint.2003.09.006
14. Luo J, Robinson JP, Shi R. Acrolein-induced cell death in PC12 cells: role of
mitochondria-mediated oxidative stress. Neurochem Int. (2005a) 47:449–57.
doi: 10.1016/j.neuint.2005.07.002
15. Luo J, Shi R. Acrolein induces oxidative stress in brain mitochondria.
Neurochem Int. (2005) 46:243–52. doi: 10.1016/j.neuint.2004.09.001
16. Hamann K, Durkes A, Ouyang H, Uchida K, Pond A, Shi R. Critical role
of acrolein in secondary injury following ex vivo spinal cord trauma. J
Neurochem. (2008a) 107:712–21. doi: 10.1111/j.1471-4159.2008.05622.x
17. Hamann K, Nehrt G, Ouyang H, Duerstock B, Shi R. Hydralazine inhibits
compression and acrolein-mediated injuries in ex vivo spinal cord. J
Neurochem. (2008b) 104:708–718. doi: 10.1111/j.1471-4159.2007.05002.x
18. Shi Y, Sun W, McBride JJ, Cheng JX, Shi R. Acrolein induces myelin
damage in mammalian spinal cord. J Neurochem. (2011) 117:554–64.
doi: 10.1111/j.1471-4159.2011.07226.x
19. Khan MA. Effect of hydralazine in hypertension. Br Med J. (1953) 1:27–9.
doi: 10.1136/bmj.1.4800.27
20. Reece PA. Hydralazine and related compounds: chemistry, metabolism, and
mode of action.Med Res Rev. (1981) 1:73–96. doi: 10.1002/med.2610010105
21. Burcham PC, Kerr PG, Fontaine F. The antihypertensive hydralazine
is an efficient scavenger of acrolein. Redox Rep. (2000) 5:47–49.
doi: 10.1179/rer.2000.5.1.47
22. Burcham PC, Kaminskas LM, Fontaine FR, Petersen DR, Pyke SM.
(2002). Aldehyde-sequestering drugs: tools for studying protein
damage by lipid peroxidation products. Toxicology 181–182:229–236.
doi: 10.1016/S0300-483X(02)00287-1
23. Liu-Snyder P, Borgens RB, Shi R. Hydralazine rescues PC12 cells
from acrolein-mediated death. J Neurosci Res. (2006) 84:219–27.
doi: 10.1002/jnr.20862
24. Carmella SG, Chen M, Zhang Y, Zhang S, Hatsukami DK, Hecht SS.
Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in
human urine by liquid chromatography-atmospheric pressure chemical
ionization tandem mass spectrometry: effects of cigarette smoking. Chem Res
Toxicol. (2007) 20:986–90. doi: 10.1021/tx700075y
25. Schettgen T, Musiol A, Kraus T. Simultaneous determination of mercapturic
acids derived from ethylene oxide (HEMA), propylene oxide (2-HPMA),
acrolein (3-HPMA), acrylamide (AAMA) and N,N-dimethylformamide
(AMCC) in human urine using liquid chromatography/tandem mass
spectrometry. Rapid Commun Mass Spectrom. (2008) 22:2629–38.
doi: 10.1002/rcm.3659
26. Yan W, Byrd GD, Brown BG, Borgerding MF. Development and validation of
a direct LC-MS-MS method to determine the acrolein metabolite 3-HPMA in
urine. J Chromatogr Sci. (2010) 48:194–9. doi: 10.1093/chromsci/48.3.194
27. Zheng L, Park J, Walls M, Tully M, Jannasch A, Cooper B, et al. Determination
of urine 3-HPMA, a stable acrolein metabolite in a rat model of spinal cord
injury. J Neurotrauma (2013) 30:1334–41. doi: 10.1089/neu.2013.2888
28. Luo J, Uchida K, Shi R. Accumulation of acrolein-protein adducts
after traumatic spinal cord injury. Neurochem Res. (2005b) 30:291–295.
doi: 10.1007/s11064-005-2602-7
29. Tully M, Shi R. New Insights in the Pathogenesis of Multiple Sclerosis—
Role of Acrolein in Neuronal and Myelin Damage. Int J Mole Sci. (2013)
14:20037–47. doi: 10.3390/ijms141020037
30. Due MR, Park J, Zheng L, Walls M, Allette YM, White FA, et al. Acrolein
involvement in sensory and behavioral hypersensitivity following spinal cord
injury in the rat. J Neurochem. (2014) 128:776–86. doi: 10.1111/jnc.12500
31. Park J, Zheng L, Marquis A, Walls M, Duerstock B, Pond A, et al.
Neuroprotective role of hydralazine in rat spinal cord injury-attenuation
Frontiers in Neurology | www.frontiersin.org 8 June 2018 | Volume 9 | Article 420
Tully et al. Acrolein in EAE and MS
of acrolein-mediated damage. J Neurochem. (2014b) 129:339–49.
doi: 10.1111/jnc.12628
32. Tully M, Zheng L, Shi R. (2014b). Acrolein detection: potential theranostic
utility in multiple sclerosis and spinal cord injury. Expert Rev Neurother.
14:679–85. doi: 10.1586/14737175.2014.918849
33. Tully M, Zheng L, Acosta G, Tian R, Shi R. Acute systemic accumulation of
acrolein in mice by inhalation at a concentration similar to that in cigarette
smoke. Neurosci Bull. (2014a) 30:1017–24. doi: 10.1007/s12264-014-1480-x
34. Kalyvas A, David S. Cytosolic phospholipase A2 plays a key role in the
pathogenesis of multiple sclerosis-like disease. Neuron (2004) 41:323–35.
doi: 10.1016/S0896-6273(04)00003-0
35. Eckert E, Drexler H, Goen T. Determination of six hydroxyalkyl
mercapturic acids in human urine using hydrophilic interaction liquid
chromatography with tandem mass spectrometry (HILIC-ESI-MS/MS).
J Chromatogr B Analyt Technol Biomed Life Sci. (2010) 878:2506–14.
doi: 10.1016/j.jchromb.2009.09.003
36. Leung G, Tully M, Tang J, Wu S, Shi R. Elevated axonal membrane
permeability and its correlation with motor deficits in an animal
model of multiple sclerosis. Transl Neurodegener. (2017) 6:5.
doi: 10.1186/s40035-017-0075-7
37. Olechowski CJ, Truong JJ, Kerr BJ. Neuropathic pain behaviours in a chronic-
relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain
(2009) 141:156–64. doi: 10.1016/j.pain.2008.11.002
38. Burcham PC, Pyke SM. Hydralazine inhibits rapid acrolein-induced
protein oligomerization: role of aldehyde scavenging and adduct trapping
in cross-link blocking and cytoprotection. Mol Pharmacol. (2006) 69:
1056–65. doi: 10.1124/mol.105.018168
39. Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G. Aldehyde
load in ischemia-reperfusion brain injury: neuroprotection by neutralization
of reactive aldehydes with phenelzine. Brain Res. (2006) 1122:184–90.
doi: 10.1016/j.brainres.2006.09.003
40. Galvani S, Coatrieux C, Elbaz M, Grazide MH, Thiers JC, Parini A, et al.
Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives.
Free Radic Biol Med. (2008) 45:1457–67. doi: 10.1016/j.freeradbiomed.2008.
08.026
41. Chen Z, Park J, Butler B, Acosta G, Vega-Alvarez S, Zheng L, et al. Mitigation
of sensory and motor deficits by acrolein scavenger phenelzine in a rat
model of spinal cord contusive injury. J Neurochem. (2016) 138:328–38.
doi: 10.1111/jnc.13639
42. Tian R, Shi R. Dimercaprol is an acrolein scavenger that mitigates
acrolein-mediated PC-12 cells toxicity and reduces acrolein in rat following
spinal cord injury. J Neurochem. (2017) 141:708–20. doi: 10.1111/jnc.
14025
Conflict of Interest Statement: RS is the co-founder and DM is the scientific
advisor of Neuro Vigor, a start-up company with business interests of developing
effective therapies for CNS neurodegenerative diseases and trauma.
The remaining authors declare that work was carried out in the absence of
any financial relationships which could be construed as a conflict of interest.
Copyright © 2018 Tully, Tang, Zheng, Acosta, Tian, Hayward, Race, Mattson and
Shi. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 9 June 2018 | Volume 9 | Article 420
